Navigation Links
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Date:12/8/2008

as in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release inclu
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products
2. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
3. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
4. Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations
5. La Rabida Children's Hospital to Host Three-Day Course on Gait Treatment Options for Children with Cerebral Palsy
6. Three Chef-Dietitians Win CanolaInfo Recipe Contest
7. Three Chicago Area Fertility Agencies Launch Shared Risk Program
8. Innerscope Research Strengthens Management Team With Three Executive Appointments
9. Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obamas First Term
10. New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
11. Three Community Leaders to Receive Foundations 2008 California Peace Prize
Post Your Comments:
*Name:
*Comment:
*Email: